Superior Efficacy of Enteric-coated Mycophenolate vs Mycophenolate Mofetil in De Novo Transplant Recipients: Pooled Analysis

Transplantation Proceedings

Volumn 42, Issue 4, 2010, Pages 1325-1328

  Salvadori, M ^a   Bertoni, E ^a   Budde, K ^b   Holzer, H ^c   Civati, G ^d   Lien, B ^e   Arns, W ^f  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF GRAZ   (Austria)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ENTERIC COATED TABLET; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; FEMALE; GASTROINTESTINAL DISEASES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TABLETS, ENTERIC-COATED;

EID: 77952626606     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.03.044     Document Type: Article

References (16)

1. Budde K., Curtis J., Knoll G., et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 4 (2004) 237
2. Salvadori M., Holzer H., de Mattos A., et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 4 (2004) 231
3. Budde K., Bauer S., Hambach P., et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 7 (2007) 888
4. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Safety 24 (2001) 645
5. Shipkova M., Armstrong V.W., Oellerich M., et al. Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol 1 (2005) 505
6. Arslan H., Inci E.K., Azap O.K., et al. Etiologic agents of diarrhea in solid organ recipients. Transpl Infect Dis 9 (2007) 270
7. Kamar N., Oufroukhi L., Faure P., et al. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium. Nephrol Dial Transplant 20 (2005) 2231
8. Bunnapradist S., Lentine K.L., Burroughs T.E., et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 82 (2006) 102
9. Pelletier R.P., Akin B., Henry M.L., et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 17 (2003) 200
10. Knoll G.A., MacDonald I., Khan A., et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 14 (2003) 2381
11. Cooper M., Deering K.L., Slakey D.P., et al. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients. Transplantation 88 (2009) 514
12. Sollinger H.W., Sundberg A.K., Leverson G., et al. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: A large single-center comparison of dose adjustments and outcomes in kidney transplant recipients. Transplantation 89 (2010) 446
13. Vitko S., Margreiter R., Weimar W., et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 78 (2004) 1532
14. Lorber M.I., Mulgaonkar S., Butt K.M., et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 80 (2005) 244
15. Legendre C., Cohen D., Zeier M., et al. Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies. Transplant Proc 39 (2007) 1386
16. Pietruck F., Abbud-Filho M., Vathsala A., et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable maintenance renal transplant patients: pooled results from three international, multicenter studies. Transplant Proc 39 (2007) 103